Page 336 - Binder2

The global health implications are massive.
But so is the strategic disruption.

Why This Threatens Pharma’s Grip

The pharmaceutical industry has long exerted control
through supply chain dominance. Centralized production
creates dependency. If you want access to a biologic, you
buy it from a company that produces it in a handful of
certified plants—often located in wealthy countries.

This creates not just market leverage, but political leverage.
It makes access contingent. Negotiable. Unequal.

But with edible biologics, that control dissolves.
Suddenly, a health ministry, university, or even a nonprofit
can produce what it needs—locally, affordably, and at
scale.

The model becomes open-source in spirit, if not in IP.
Production becomes a public health function, not a
corporate one.

And for an industry that profits from exclusivity, that’s not
just inconvenient.
It’s existential.

In traditional pharmaceutical manufacturing, the supply
chain is both an asset and a liability. While it enables
global reach, it also introduces massive points of
vulnerability. Drug launches have been delayed—and entire
therapeutic programs derailed—because of contamination

334